A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis from a randomized controlled trial evaluated the effects of dapagliflozin on renal glucose uptake in patients with type 2 diabetes and stable coronary artery disease. After 4 weeks, a significant reduction in SUV_peak was observed in the dapagliflozin group (p = 0.028), suggesting decreased glucose uptake during insulin stimulation.
Key findings
- Dapagliflozin treatment resulted in a significant reduction in SUV_peak (p = 0.028).
- The placebo group showed stable or slightly increased SUV values.
- A consistent directional pattern in renal SUV was noted across all parameters in the dapagliflozin group.
Why it matters
Understanding the mechanisms by which SGLT-2 inhibitors affect renal glucose uptake can inform treatment strategies for patients with type 2 diabetes, particularly those at risk for renal complications.
What to keep in mind
The study had a limited sample size (n = 7 per group), which may affect the generalizability of the findings.